AAM
ADMA icon

Advisors Asset Management’s ADMA Biologics ADMA Stock Holding History

Advisors Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.7K Buy
7,250
+123
+2% +$1.12K ﹤0.01% 1278
2026
Q1 		$64.2K Buy
7,127
+2,335
+49% +$36.8K ﹤0.01% 1277
2025
Q4 		$87.4K Buy
4,792
+1,769
+59% +$29.8K ﹤0.01% 1246
2025
Q3 		$44.3K Buy
3,023
+1,967
+186% +$33.7K ﹤0.01% 1300
2025
Q2 		$19.2K Buy
+1,056
New +$21.5K ﹤0.01% 1342

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Advisors Asset Management's ADMA Position: Q2 2026 in Review

Advisors Asset Management increased its ADMA Biologics (ADMA) stake by 1.7% in Q2 2026, buying an estimated $1.12K and bringing the position to 7,250 shares worth $60.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1278.

Advisors Asset Management first reported a position in ADMA in Q2 2025 and has held it in 5 quarters since. The position peaked at $87.4K in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Advisors Asset Management held 7,250 shares of ADMA Biologics worth $60.7K as of Q2 2026.
  • Advisors Asset Management bought 123 ADMA Biologics shares in Q2 2026, an estimated $1.12K.
  • ADMA Biologics made up ﹤0.01% of Advisors Asset Management's portfolio in Q2 2026, its #1278 holding.
  • Advisors Asset Management first reported a position in ADMA Biologics in Q2 2025 and has held it in 5 quarters since.
  • Advisors Asset Management's ADMA Biologics position peaked at $87.4K in Q4 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.